Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

2361. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40

Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 UK Prospective Diabetes Study Group Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Blood pressure control in hypertensive patients with type 2 diabetes. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Hypertensive patients with type 2 diabetes. The mean (SD) age of patients was 56.4(8.1) years. Setting

1998 NHS Economic Evaluation Database.

2362. Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management

Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management Penfornis A, Millot L Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Outpatient approach to initiating insulin therapy in insulin-requiring Type 2 diabetic patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Type 2 diabetic patients

1998 NHS Economic Evaluation Database.

2363. Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus: a decision-analytical approach

Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus: a decision-analytical approach Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus: a decision-analytical approach Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus (...) : a decision-analytical approach Banz K, Dinkel R, Hanefeld M, Schwanebeck U Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Acarbose or glibenclamide therapy in patients with type 2 (non-insulin-dependent) diabetes mellitus. Type

1998 NHS Economic Evaluation Database.

2364. The cost-effectiveness of screening for type 2 diabetes

The cost-effectiveness of screening for type 2 diabetes The cost-effectiveness of screening for type 2 diabetes The cost-effectiveness of screening for type 2 diabetes CDC Diabetes Cost-Effectiveness Study Group Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Screening for type 2 diabetes mellitus using a fasting plasma glucose test (FPGT) confirmed by an oral glucose tolerance test (OGTT)(for persons testing positive to the first test). Type of intervention Screening. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population A hypothetical population, aged 25 years and above, modelled on the general US population without diagnosed diabetes and of whom a percentage (forming a cohort

1998 NHS Economic Evaluation Database.

2365. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients

Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients Hendry B M, Viberti G C, Hummel S, Bagust A, Piercy J Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using an angiotensin-converting enzyme (ACE)inhibitor, captopril (25 mg, 3 times a day) to slow progression of renal failure in diabetic patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study

1997 NHS Economic Evaluation Database.

2366. Metformin: an antihyperglycemic agent for treatment of type II diabetes

A. Metformin: an antihyperglycemic agent for treatment of type II diabetes. Annals of Pharmacotherapy 1996; 30(2): 158-164 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Diabetes Mellitus, Type 2 /drug therapy; Humans; Hypoglycemic Agents /adverse effects /economics /pharmacokinetics /pharmacology /therapeutic use; Metformin /adverse effects /economics /pharmacokinetics /pharmacology /therapeutic use AccessionNumber 11996000475 Date bibliographic record published 31/01/1997 Date abstract (...) Metformin: an antihyperglycemic agent for treatment of type II diabetes Metformin: an antihyperglycemic agent for treatment of type II diabetes Metformin: an antihyperglycemic agent for treatment of type II diabetes Melchior W R, Jaber L A Authors' objectives To review the comparative efficacy of metformin, sulfonylureas, and insulin in the treatment of patients with type II diabetes. Searching MEDLINE was searched from 1966 to 1994 for articles published in English, French or German, using

1996 DARE.

2367. Promoting weight loss in type II diabetes

M, Upchurch S, Ramirez G, Anding R. Promoting weight loss in type II diabetes. Diabetes Care 1996; 19(6): 613-624 PubMedID Other publications of related interest 1. Glass GV, McGraw B, Smith ML. Meta-analysis in social research. Beverly Hills (CA): Sage Publications; 1981. 2. Hedges LV, Olkin I. Statistical methods for meta-analysis. New York: Academic Press; 1985. 3. Richter B. Meta-analysis: dietary strategies alone reduce weight best in NIDDM. ACP J Club 1997;126:5. Indexing Status Subject (...) indexing assigned by NLM MeSH Blood Pressure; Body Weight; Cholesterol /blood; Diabetes Mellitus, Type 2 /blood /physiopathology /therapy; Diet, Diabetic; Diet, Reducing; Exercise; Health Promotion; Humans; Lipoproteins /blood; Longitudinal Studies; Middle Aged; Treatment Outcome; Weight Loss AccessionNumber 11996001033 Date bibliographic record published 30/09/1998 Date abstract record published 30/09/1998 Record Status This is a critical abstract of a systematic review that meets the criteria

1996 DARE.

2368. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomised placebo-controlled trials

and quantitative methods. In: Moody L, editor. Advanced nursing science through research. Vol 2. Thousand Oaks (CA): Sage; 1990. p. 70-107. 2. Pugh J, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? Diabetes Care 1992;15:853-959.(DARE abstract number 11994002624). Indexing Status Subject indexing assigned by NLM MeSH Blood Glucose /metabolism; Body Weight; C-Peptide /blood; Diabetes Mellitus, Type 2 /drug therapy /physiopathology (...) Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomised placebo-controlled trials Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomised placebo-controlled trials Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomised placebo-controlled trials Johnson J L, Wolf S L, Kubadi U M Authors' objectives To assess the efficacy

1996 DARE.

2369. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus

Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus Steindel B S, Roe T R, Costin G, Carlson M, Kaufman F R Record Status This is a critical abstract (...) with poorly controlled diabetes for 2 - 7 years. Poor control was defined as at least 2 episodes of diabetic ketoacidosis per year, chronically elevated glycosylated haemoglobin levels and widely fluctuating blood glucose levels. Setting Children's Hospital Los Angeles Diabetes Center, USA. The cost analysis referred to the same setting. Dates to which data relate No dates were given in the text. Source of effectiveness data The evidence was based on a single study. Link between effectiveness and cost

1995 NHS Economic Evaluation Database.

2370. Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for Type 1 (insulin-dependent) diabetes mellitus in Moscow: blood glucose versus urine glucose self-monitoring

, Germany. Bibliographic details Starostina E G, Antsiferov M, Galstyan G R, Trautner C, Jorgens V, Muhlhauser I, Berger M, Dedov I I. Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for Type 1 (insulin-dependent) diabetes mellitus in Moscow: blood glucose versus urine glucose self-monitoring. Diabetologia 1994; 37(2): 170-176 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Adult; Analysis of Variance; Blood Glucose Self-Monitoring (...) Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for Type 1 (insulin-dependent) diabetes mellitus in Moscow: blood glucose versus urine glucose self-monitoring Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for Type 1 (insulin-dependent) diabetes mellitus in Moscow: blood glucose versus urine glucose self-monitoring Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for Type 1

1994 NHS Economic Evaluation Database.

2371. Prompting the clinical care of non-insulin dependent (type II) diabetic patients in an inner city area: one model of community care. (PubMed)

Prompting the clinical care of non-insulin dependent (type II) diabetic patients in an inner city area: one model of community care. To evaluate the effectiveness and acceptability of centrally organised prompting for coordinating community care of non-insulin dependent diabetic patients.Randomised single centre trial. Patients allocated to prompted care in the community or to continued attendance at hospital diabetic clinic (controls). Median follow up two years.Two hospital outpatient clinics (...) , 38 general practices, and 11 optometrists in the catchment area of a district general hospital in Islington.181 patients attending hospital outpatient clinics.There is no difference in process of medical care measures and medical outcome between prompted community care and hospital clinic care.14 hospital patients failed to receive a single review in the clinic as compared with three patients in the prompted group (chi 2 = 6.1, df = 1; p = 0.013). Follow up for retinal screening was better

Full Text available with Trip Pro

1993 BMJ

2372. Insulin prophylaxis in individuals at high risk of type I diabetes. (PubMed)

Insulin prophylaxis in individuals at high risk of type I diabetes. Prevention of type I diabetes is now a practical goal thanks to the ability to define confidently a high-risk group and the success of preventive strategies in animal models. We describe here a pilot trial of low-dose insulin to prevent diabetes in relatives of patients with type I diabetes.

1993 Lancet

2373. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. (PubMed)

Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Tight blood glucose control has been speculated to reduce late complications in insulin-dependent diabetics but results from individual studies have been inconsistent. We have done a meta-analysis of sixteen randomised trials of intensive therapy to estimate its impact on the progression of diabetic retinopathy and nephropathy and the risks of severe side-effects. In the intensive therapy group (...) treated patients. The incidence of diabetic ketoacidosis increased by 12.6 episodes per 100 person-years (95% Cl, 8.7-16.5) in the patients on continuous subcutaneous insulin infusion. Long-term intensive blood glucose control significantly reduces the risk of diabetic retinopathy and nephropathy progression but long-term continuous subcutaneous insulin infusion was associated with an increased incidence of diabetic ketoacidosis, and intensive therapy may cause more severe hypoglycaemic reactions.

1993 Lancet

2374. Rotation of the anatomic regions used for insulin injections and day-to-day variability of plasma glucose in type I diabetic subjects. (PubMed)

Rotation of the anatomic regions used for insulin injections and day-to-day variability of plasma glucose in type I diabetic subjects. Treatment of type I diabetes mellitus is hindered by the often large fluctuations in blood glucose concentration experienced by affected individuals. To determine to what extent day-to-day variation in blood glucose levels can be reduced if insulin is injected in the same anatomic region rather than in different regions using a rotational scheme, as is commonly (...) recommended, 12 type I diabetic subjects were studied. Insulin injections were given in the abdomen for 3 days and rotated among arms, abdomen, and thighs for 3 days using a crossover design with random assignment of treatment order. Blood samples for measurement of plasma glucose levels were obtained at nine scheduled times on each day. Insulin dose, diet, and physical activity were held constant for each subject. During the abdominal injection period, the mean SD of plasma glucose levels and the mean

1990 JAMA

2375. Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. (PubMed)

Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. To determine the effect of moderate dietary sodium restriction on the hypertension of non-insulin-dependent (type II) diabetes.Randomised parallel controlled study of moderate sodium restriction for three months compared with usual diabetic diet, followed by randomised double blind crossover trial of sustained (...) release preparation of sodium for one month versus placebo for one month in patients continuing with sodium restriction.Patients attending diabetic outpatient clinic of city hospital.Thirty four patients with established type II diabetes complicated by mild hypertension (systolic blood pressure greater than 160 mm Hg or diastolic pressure greater than 95 mm Hg on three consecutive occasions). Patients already taking antihypertensive agents (but not diuretics) not barred from study provided

Full Text available with Trip Pro

1989 BMJ

2376. One-year trial of a remote-controlled implantable insulin infusion system in type I diabetic patients. Point Study Group. (PubMed)

One-year trial of a remote-controlled implantable insulin infusion system in type I diabetic patients. Point Study Group. Twenty remote-controlled insulin pumps (Siemens AG) were implanted into insulin-dependent type I diabetic patients for a one-year feasibility trial in four centres. The total observation time was 18.2 patient-years. Three pumps had to be prematurely removed after 101, 141, and 236 days. Patients self-monitored blood glucose levels with a mean of 5.5 (range 1-17) measurements

1988 Lancet

2377. Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial. (PubMed)

Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial. This study examined the potential beneficial effects of the addition of a second-generation sulfonylurea to insulin therapy for poorly controlled type II diabetes. A randomized, double-blind, crossover experimental design was utilized in 16 type II diabetic patients for a period of eight months. Treatment with glyburide, 20 mg/d (plus insulin), compared with placebo (...) (plus insulin) resulted in a significant reduction in mean basal glucose (232 +/- 12 vs 262 +/- 11 mg/dL [12.8 vs 14.4 mmol/L]) and hemoglobin A1C (10.2% +/- 0.5% vs 10.9% +/- 03%) concentrations. Concomitant with this change, basal C-peptide and free insulin values increased with glyburide therapy, but this pharmacological agent did not alter the ability of the patient's erythrocytes to bind insulin. We conclude that in type II diabetic subjects receiving more than 28 units of insulin per day

1987 JAMA

2378. Metabolic effects of dietary fructose and sucrose in types I and II diabetic subjects. (PubMed)

Metabolic effects of dietary fructose and sucrose in types I and II diabetic subjects. To learn more about the metabolic effects of dietary fructose and sucrose, 12 type I and 12 type II diabetic subjects were fed three isocaloric (or isoenergic) diets for eight days each according to a randomized, crossover design. The three diets provided, respectively, 21% of the energy as fructose, 23% of the energy as sucrose, and almost all carbohydrate energy as starch. The fructose diet resulted (...) in significantly lower one- and two-hour postprandial plasma glucose levels, overall mean plasma glucose levels, and urinary glucose excretion in both type I and type II subjects than did the starch diet. There were no significant differences between the sucrose and starch diets in any of the measures of glycemic control in either subject group. The fructose and sucrose diets did not significantly increase serum triglyceride values when compared with the starch diet, but both increased postprandial serum

1986 JAMA

2379. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. (PubMed)

Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. 14 hypertensive men with type II diabetes sequentially received, in random order, hydrochlorothiazide 50 mg twice a day, propranolol 80 mg twice a day, and both drugs in combination. The 3-week treatment periods were separated by a 1-week washout period. Hydrochlorothiazide significantly increased fasting glucose by 31% (p less than 0.05) and glycosylated (...) and propranolol thus seems to cause serious disturbances in glycaemic control in type II diabetics by mechanisms independent of insulin secretion.

1985 Lancet